Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE vs OFIRMEV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ammonium chloride provides chloride ions to correct hypochloremic metabolic alkalosis and acts as a systemic acidifying agent. It is metabolized to urea and hydrochloric acid in the liver, thereby increasing hydrogen ion concentration in plasma and lowering p H.
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Treatment of hypochloremic metabolic alkalosis,Acidification of urine (e.g., to enhance renal clearance of basic drugs like amphetamine or quinidine),Adjunct in the treatment of severe refractory metabolic alkalosis
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
Adults: 0.9% ammonium chloride in normal saline, intravenous infusion at a rate of 0.5-1 m L/kg/hour, typically 500-1000 m L over 4-8 hours, adjusted based on serum chloride and p H. Maximum infusion rate: 1 m L/kg/hour.
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
Variable; approximately 2-4 hours depending on renal function and acid-base status; prolonged in renal impairment.
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Hepatic: ammonium chloride is converted to urea (via the urea cycle) and hydrochloric acid; enzymes include carbamoyl phosphate synthetase I, ornithine transcarbamylase, and arginase.
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Renal: >95% as ammonium and chloride ions; minimal biliary/fecal elimination.
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
<10% bound to plasma proteins.
10-25% bound to albumin at therapeutic concentrations.
0.3-0.5 L/kg; distributes primarily in extracellular fluid.
0.8-1.0 L/kg. Indicates distribution into total body water.
Oral: ~100% (well absorbed); IV: 100% (bioequivalent).
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
GFR <30 m L/min: Avoid use due to risk of hyperchloremic metabolic acidosis and ammonium accumulation. GFR 30-50 m L/min: Initiate at 50% of standard rate, monitor serum ammonium and electrolytes. No adjustment for GFR >50 m L/min.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
Child-Pugh Class B or C: Contraindicated due to impaired urea synthesis and risk of hepatic encephalopathy. Child-Pugh Class A: Caution; monitor serum ammonia and reduce infusion rate by 50%.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
Children: Initial dose 0.5-1 m Eq/kg of ammonium ion (1 m Eq/kg = 0.1 m L/kg of 0.9% solution) as a slow IV infusion over 4-6 hours. Maximum rate: 0.5 m L/kg/hour. Titrate based on serum p H and chloride.
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
Use with caution due to age-related decline in renal function; start at lower end of dosing range (0.5 m L/kg/hour) and monitor renal function and electrolytes closely. Adjust dose per renal function.
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
None
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Use with caution in patients with hepatic impairment (risk of hyperammonemia and hepatic encephalopathy), renal impairment (risk of metabolic acidosis), or respiratory acidosis. Monitor serum ammonia, chloride, bicarbonate, and p H levels. Rapid infusion may cause local irritation, phlebitis, and metabolic acidosis.
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
Severe hepatic insufficiency (cirrhosis, hepatitis), severe renal impairment (anuria, oliguria), primary respiratory acidosis, hypernatremia, and known hypersensitivity to any component.
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
Avoid high-sodium foods or salt substitutes that contain potassium, as this may affect electrolyte balance. No specific food restrictions are required, but maintain a balanced diet as advised by your healthcare provider.
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
Ammonium chloride is a urine acidifier with limited data in pregnancy. It is generally considered low risk for teratogenicity based on animal studies and lack of human adverse reports. However, maternal metabolic acidosis from overdose could theoretically harm the fetus. First trimester: no known teratogenic effect. Second and third trimesters: minimal risk unless maternal acidosis occurs. Use only if clearly needed.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
Ammonium chloride is excreted into breast milk, but concentrations are low and not expected to harm the nursing infant. The M/P ratio is unknown. It is considered compatible with breastfeeding if used at recommended doses. Monitor infant for signs of acidosis if high doses are used.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
Pregnancy does not typically require dose adjustment. However, consider the increased renal clearance and plasma volume in pregnancy; monitor acid-base balance closely. No established dosing change is recommended; use the lowest effective dose.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
0.9% ammonium chloride in normal saline is an acidifying agent used to correct metabolic alkalosis. Monitor serum electrolytes, p H, and bicarbonate closely during infusion. Avoid in patients with severe hepatic or renal impairment. Administer via central line due to hypertonicity (approximately 900 m Osm/L). Can cause hyperammonemia in hepatic failure; use with caution in hypokalemia as it may exacerbate potassium loss.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
This medication is given intravenously to treat alkalosis (high blood p H).,You may experience pain or burning at the IV site; report any discomfort.,Tell your doctor if you have liver or kidney disease.,Do not take potassium supplements or salt substitutes without consulting your doctor.,Inform your healthcare provider of all medications you are taking.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
"Ammonium chloride, an acidifying agent, reduces urinary pH, which increases the renal clearance of lisdexamfetamine and its active metabolite d-amphetamine. This accelerated elimination leads to decreased systemic exposure and potentially diminished therapeutic efficacy of lisdexamfetamine. Clinically, patients may experience reduced symptom control for ADHD or binge eating disorder, requiring dose adjustments or alternative therapies."
"Sufentanil, a potent opioid analgesic, may increase renal excretion of ammonium chloride by promoting diuresis through opioid-induced release of antidiuretic hormone (ADH) and subsequent water reabsorption, leading to dilutional acidosis and enhanced ammonium excretion. This interaction can result in reduced serum ammonium levels and decreased efficacy of ammonium chloride as an acidifying agent, potentially compromising its therapeutic effect in metabolic alkalosis or urinary tract infections. Clinical outcomes may include incomplete correction of metabolic alkalosis or reduced antimicrobial activity of ammonium chloride in the urine."
"Ammonium chloride acidifies the urine, which increases the renal excretion of amphetamine by favoring its ionized form in the tubular lumen, thereby reducing its reabsorption. This leads to a decreased serum concentration of amphetamine and potentially diminished therapeutic efficacy. Clinically, patients may experience reduced mood-elevating or stimulant effects, requiring dose adjustment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE vs OFIRMEV, answered by our medical review team.
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE is a Expectorant/Systemic Acidifier that works by Ammonium chloride provides chloride ions to correct hypochloremic metabolic alkalosis and acts as a systemic acidifying agent. It is metabolized to urea and hydrochloric acid in the liver, thereby increasing hydrogen ion concentration in plasma and lowering p H.. OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE and OFIRMEV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE is: Adults: 0.9% ammonium chloride in normal saline, intravenous infusion at a rate of 0.5-1 m L/kg/hour, typically 500-1000 m L over 4-8 hours, adjusted based on serum chloride and p H. Maximum infusion rate: 1 m L/kg/hour.. The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE and OFIRMEV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE is classified as Category C. Ammonium chloride is a urine acidifier with limited data in pregnancy. It is generally considered low risk for teratogenicity based on animal studies and lack of human adverse repo. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.